Observational studyBritish journal of cancer2025
Prospective study of circulating metabolomic profiles and breast cancer incidence among predominantly premenopausal women.
Observational study in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NMR-based metabolomics analysis in breast cancer patients from Saudi Arabia: a pilot study.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAssociations between premenopausal plasma metabolites and breast cancer incidence are largely unknown.
methodsWe conducted a prospective, matched case-control study in which we measured pre-diagnostic metabolomic profiles among predominantly premenopausal women in the Nurses' Health Study II (n = 2010). Lipids, carbohydrates, and organic acid-related metabolites (n = 218) were profiled via liquid chromatography-tandem mass spectrometry. Conditional logistic regression was used to estimate odds ratios (OR) for associations between individual metabolites and breast cancer incidence. Associations with metabolite groups were assessed using metabolite set enrichment analysis (MSEA).
resultsSix individual lipid-related metabolites were nominally associated with breast cancer incidence (taurodeoxycholate [OR for per 1 standard deviation increase in metabolite level = 1.15, 95% CI = 1.04-1.28]; C16:1 cholesteryl ester [OR = 0.88, 95% CI = 0.79-0.97]; three phosphocholine (PC)-related metabolites, C34:1 PC [OR = 0.87, 95% CI = 0.78-0.98], C34:3 PC [OR = 0.88, 95% CI = 0.79-0.98], C32:1 PC [OR = 0.88, 95% CI = 0.79-0.98]; indoxyl sulfate [OR = 0.90, 95% CI = 0.82-1.00]). In MSEA analyses, triglycerides (TAGs) with <3 double bonds (normalized enrichment score (NES) = -2.54) and PCs (NES = -2.12) were inversely associated with breast cancer incidence overall and across subgroups. Phosphatidylethanolamine (PE) plasmalogens (NES = 1.83) and PC plasmalogens (NES = 2.23) were positively associated with breast cancer incidence.
conclusionsPremenopausal plasma TAGs, PCs, and plasmalogen metabolites were associated with breast cancer incidence. Further validation in independent cohorts is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.